Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

81. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110 mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation who had not previously taken an oral anticoagulant. Design Propensity weighted (inverse probability of treatment weighted) nationwide (...) cohort study. Setting Individual linked data from three nationwide registries in Denmark. Participants Patients with non-valvular atrial fibrillation filling a first prescription for an oral anticoagulant from August 2011 to February 2016. Patients who filled a prescription for a standard dose non-vitamin K antagonist oral anticoagulant (novel oral anticoagulants, NOACs) were excluded. To control for baseline differences in the population, a propensity score for receipt of either of the four

BMJ2017

82. Management of Isolated Calf DVTs with Anticoagulation

Management of Isolated Calf DVTs with Anticoagulation Emergency Medicine > Journal Club > Archive > August 2016 Toggle navigation August 2016 Management of Isolated Calf DVTs with Anticoagulation Vignette Mr. M is a 53-year-old patient with a history of high blood pressure and high cholesterol who flew back to St. Louis from Shanghai five days ago. Two days after getting back he noted pain and swelling in his left calf, which he thought was due to a muscle strain while getting off (...) of years that spoke about the controversy surrounding this dogma. You send Mr. P home and recommend repeat dopplers in 5-7 days, but later decide to search the literature in order to make your own evidence-based decision... PICO Question Population: Adult patients with isolated calf DVT distal to the popliteal veins Intervention: Therapeutic anticoagulation (heparin, low molecular weight heparin, factor Xa inhibitor, direct thrombin inhibitor, or vitamin K antagonist) Comparison: No anticoagulation

Washington University Emergency Medicine Journal Club2017

83. Anticoagulants in non-valvular atrial fibrillation

Anticoagulants in non-valvular atrial fibrillation Anticoagulants in non-valvular atrial fibrillation Anticoagulants in non-valvular atrial fibrillation Van Brabandt H, San Miguel L, Fairon N, Vaes B, Henrard S, Boshnakova A, Cook R, Davies R, Karnad A, Lovell A, Dubois C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Van Brabandt H, San (...) Miguel L, Fairon N, Vaes B, Henrard S, Boshnakova A, Cook R, Davies R, Karnad A, Lovell A, Dubois C. Anticoagulants in non-valvular atrial fibrillation. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports. 2017 Authors' conclusions • International practice guidelines recommend prescribing anticoagulants to patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score ≥ 2 (for men) and score ≥ 3 (for women). For a CHA2DS2-VASc score = 0 they are best not prescribed. In patients

Health Technology Assessment (HTA) Database.2017

84. Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines

Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines | CADTH.ca Find the information you need Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines (...) Idarucizumab for Reversing Anticoagulation in Adults Treated with Dabigatran: A Review of the Clinical Effectiveness, Cost-effectiveness, and Guidelines Published on: January 31, 2017 Project Number: RD0035-000 Product Line: Research Type: Drug Report Type: Peer-reviewed summary with critical appraisal Result type: Report Question What is the comparative effectiveness and safety of idarucizumab versus standard supportive care for reversing the anticoagulation state in adults treated with dabigatran

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

86. Myths and Realities: Is My Cirrhotic Patient Auto-anticoagulated?

Myths and Realities: Is My Cirrhotic Patient Auto-anticoagulated? Myths and Realities: Is My Cirrhotic Patient Auto-anticoagulated? | Clinical Correlations Myths and Realities: Is My Cirrhotic Patient Auto-anticoagulated? January 12, 2017 By B. Corbett Walsh, MD Peer Reviewed Case: A 65 year-old man with cirrhosis is admitted to the ICU for severe pneumonia. His hepatic dysfunction is chronically severe, as indicated by a MELD score of 31, and he has a stable thrombocytopenia of 110,000 (...) platelets/ml. Should this patient be on DVT prophylaxis? MYTH: Patients with severe hepatic dysfunction resulting in a significantly elevated INR are auto-anticoagulated and protected against venous thromboembolic events. The liver is responsible for a plethora of processes: metabolic (carbohydrate and lipid metabolism, regulating the levels of glucose in the blood), storage (glycogen, triglycerides, iron, vitamins, minerals, etc), catabolic (hormones, proteins, drugs, toxins, alcohol), excretory (bile

Clinical Correlations2017

88. Anticoagulation - oral

Anticoagulation - oral Anticoagulation - oral - NICE CKS Clinical Knowledge Summaries Share Anticoagulation - oral: Summary There are five oral anticoagulants licensed for use in the UK: warfarin, apixaban, dabigatran, edoxaban and rivaroxaban. Apixaban, dabigatran, edoxaban and rivaroxaban are newer anticoagulants which may be prescribed instead of warfarin for people with non-valvular atrial fibrillation (NVAF): Apixaban, dabigatran, edoxaban and rivaroxaban have been approved by the National (...) . bleeding). Assess for the presence of thromboembolic events (e.g. symptoms of stroke, or breathlessness which may suggest a pulmonary embolism). The most common adverse effect of anticoagulants is bleeding; however, while there is an antidote for warfarin, of the new anticoagulants, there is currently only an antidote for dabigatran. Management of a bleeding complication in secondary care consists of stopping treatment and general haemostatic measures, such as mechanical compression and surgical

NICE Clinical Knowledge Summaries2017

89. Qualitative study?other: Patient self-testing and self-management of anticoagulation is safe and patients are satisfied with these programmes

Qualitative study?other: Patient self-testing and self-management of anticoagulation is safe and patients are satisfied with these programmes Patient self-testing and self-management of anticoagulation is safe and patients are satisfied with these programmes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patient self-testing and self-management of anticoagulation is safe and patients are satisfied with these programmes Article Text Adult

Evidence-Based Nursing (Requires free registration)2017

90. Qualitative study?other: Individualised assessment is required to establish the most appropriate anticoagulation option for patients

Qualitative study?other: Individualised assessment is required to establish the most appropriate anticoagulation option for patients Individualised assessment is required to establish the most appropriate anticoagulation option for patients | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Individualised assessment is required to establish the most appropriate anticoagulation option for patients Article Text Adult nursing Qualitative study

Evidence-Based Nursing (Requires free registration)2017

91. Observational study: In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7?8 weeks after ICH

Observational study: In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7?8 weeks after ICH In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7–8 weeks after ICH | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7–8 weeks after ICH Article Text Therapeutics

Evidence-Based Medicine (Requires free registration)2017

92. Cohort study: Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation

Cohort study: Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation Article Text Therapeutics/Prevention Cohort study Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients

Evidence-Based Medicine (Requires free registration)2017

95. Systematic review: Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy

Systematic review: Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy Article Text Community and primary care nursing Systematic review Patients who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy Michelle

Evidence-Based Nursing (Requires free registration)2017

98. Long-acting anticoagulant rodenticides (superwarfarins) toxicity - emergency management

Long-acting anticoagulant rodenticides (superwarfarins) toxicity - emergency management

DynaMed Plus2017

99. Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

Antiplatelet and anticoagulant drugs for ST-elevation myocardial infarction (STEMI)

DynaMed Plus2017

100. Antiplatelet and anticoagulant drugs for elective percutaneous coronary intervention (PCI)

Antiplatelet and anticoagulant drugs for elective percutaneous coronary intervention (PCI)

DynaMed Plus2017